BTIG reiterated coverage on OrthoPediatrics with a new price target
$KIDS
Medical/Dental Instruments
Health Care
BTIG reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $68.00 from $75.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/25/2024 | $39.00 → $31.00 | Buy → Hold | Truist |
| 3/3/2022 | $83.00 → $65.00 | Buy | Needham |
| 12/22/2021 | $75.00 → $68.00 | Buy | BTIG |
| 12/21/2021 | $78.00 → $75.00 | Buy | Truist Securities |
| 8/6/2021 | $70.00 → $77.00 | Market Outperform | JMP Securities |
WARSAW, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, March 4, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company gained distribution rights to bring additional bracing solutions to the US market through its OrthoPediatrics Specialty Bracing (OPSB) division. OrthoPediatrics' OPSB division has established a distribution agreement with Thrive Orthopedics LLC focused on three unique pediatric orthotic solutions. The Thrive Orthopedics F3 Hero Pediatric AFO is a lightweight carbon fiber ankle foot orthosis that provides the stability needed to improve walking while allowing
Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-YearInitiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the fourth quarter and full year ended December 31, 2024, issued 2025 financial guidance and provided business updates. 2024 Business and Financial Highlights: Helped over 34,000 children in the fourth quarter 2024, the Company has now helped over 1.1 million children
WARSAW, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, March 4, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Business Highlights Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarterGrew w
WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
Truist downgraded OrthoPediatrics from Buy to Hold and set a new price target of $31.00 from $39.00 previously
Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $65.00 from $83.00 previously
BTIG reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $68.00 from $75.00 previously
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the "Alliance for Pediatric Device Innovation" (APDI), to advice the development and commercialization of medical devices designed for children. Along with Children's National, APDI consortium members include Johns Hopkins University, CIMIT at Mass General Brigham, Tufts Medical Center and Medstar Health Research Institute. The Company will serve as APDI's strategic advisor and role model for devic
New CEO Paul Mraz also joins FzioMed Inc.'s Board of Directors; Company set to accelerate growth of market leading Oxiplex® adhesion barrier products. SAN LUIS OBISPO, Calif., Jan. 3, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors. Mraz's appointment became effective Jan. 1, 2023, commensurate with the retirement of John Krelle who served in the leadership role since 2005. "On behalf of the Board of Directors, I want to thank John for
WARSAW, Ind., Oct. 20, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Jimmy D. McDonald to its board of directors, effective October 18, 2022. Mark Throdahl, Executive Chairman of OrthoPediatrics' board said, "We are pleased to have attracted an Operations executive of Jimmy's stature to our company, which has an extensive supplier network of outsourced products. Beyond his directly relevant experience, Jimmy brings a wonderful personal fit with the culture of our board and our company." Mr. McDonald currently is Vice Pr
SCHEDULE 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)